Immix Biopharma, Inc. 宣布,其近期融资所获净收益将专项用于推进其候选疗法NXC-201的临床开发,补充营运资金,以及支持公司其他一般性企业用途。
Immix Biopharma, Inc. 宣布,其近期融资所获净收益将专项用于推进其候选疗法NXC-201的临床开发,补充营运资金,以及支持公司其他一般性企业用途。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.